Clariant today announced the sale of its Pharmaceutical Fine Chemicals unit to TowerBrook Capital Partners, L.P. for a transaction value of approximately $86.8 million. The sale is part of Clariant’s strategy to focus its portfolio on core activities.  The unit manufactures building blocks, regulatory starting materials, intermediates and active pharmaceutical ingredients (APIs) for both the branded and the generic pharmaceutical industry. At the deal’s completion, the new autonomous entity will...